MedPath

H. Lee Moffitt Cancer Center and Research Institute, Inc.

H. Lee Moffitt Cancer Center and Research Institute, Inc. logo
🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Oncology Research Information Exchange Network (ORIEN) Lung Cancer Study

Completed
Conditions
Non-small Cell Lung Cancer
Lung Cancer
Interventions
Other: No Intervention
First Posted Date
2016-06-16
Last Posted Date
2023-02-27
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
75
Registration Number
NCT02803333
Locations
🇺🇸

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Facilitating Smoking Cessation With Reduced Nicotine Cigarettes

Phase 2
Completed
Conditions
Smoking Cessation
Interventions
Drug: Very Low Nicotine Content (VLNC) Cigarettes
Behavioral: One on One Counseling
First Posted Date
2016-06-10
Last Posted Date
2022-11-14
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
163
Registration Number
NCT02796391
Locations
🇺🇸

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Phase 1
Completed
Conditions
Multiple Myeloma
Interventions
Procedure: Autologous Hematopoietic Cell Transplantation (HCT)
First Posted Date
2016-05-23
Last Posted Date
2022-11-04
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
22
Registration Number
NCT02780609
Locations
🇺🇸

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

Phase 1
Active, not recruiting
Conditions
Breast Cancer
Ductal Carcinoma
Invasive Breast Carcinoma
Invasive Ductal Breast Carcinoma
Interventions
First Posted Date
2016-05-20
Last Posted Date
2025-05-22
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
50
Registration Number
NCT02779855
Locations
🇺🇸

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

A Combined Cell Therapy Approach to the Treatment of Neuroblastoma

Phase 1
Withdrawn
Conditions
Neoplasms, Nerve Tissue
Neuroblastoma
Interventions
Procedure: Autologous Hematopoietic Progenitor Cell Transplant
Biological: KLH and Tumor Lysate Pulsed DC Vaccine
First Posted Date
2016-04-20
Last Posted Date
2017-08-30
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Registration Number
NCT02745756

Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT)

Phase 2
Completed
Conditions
Multiple Myeloma
Interventions
First Posted Date
2016-03-30
Last Posted Date
2022-11-01
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
30
Registration Number
NCT02722941
Locations
🇺🇸

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Validation Study on the Impact of Decipher® Testing - VANDAAM Study

Active, not recruiting
Conditions
Prostate Cancer
Interventions
Other: Decipher® Testing
First Posted Date
2016-03-30
Last Posted Date
2025-05-14
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
240
Registration Number
NCT02723734
Locations
🇺🇸

Bay Pines VA Health care System, Bay Pines, Florida, United States

🇺🇸

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

🇺🇸

James A. Haley VA Hospital, Tampa, Florida, United States

XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma

Phase 1
Active, not recruiting
Conditions
Melanoma
Skin Cancer
Interventions
First Posted Date
2016-03-29
Last Posted Date
2025-05-22
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
26
Registration Number
NCT02721459
Locations
🇺🇸

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Pilot Testing of a Real-Time Oncogeriatric Teleconsultation System Using the Total Cancer Care™ Database

Completed
Conditions
Oncology Problem
Interventions
Other: Screening
First Posted Date
2016-03-15
Last Posted Date
2022-11-14
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
31
Registration Number
NCT02708381
Locations
🇺🇸

Lynn Cancer Institute, Boca Raton Regional Hospital, Boca Raton, Florida, United States

🇺🇸

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma

Early Phase 1
Completed
Conditions
Melanoma (Skin)
Skin Cancer
Interventions
Procedure: Surgery to Remove Tumor for Growth of TIL
Drug: CD137
Biological: TIL Infusion
First Posted Date
2016-01-11
Last Posted Date
2023-01-19
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
11
Registration Number
NCT02652455
Locations
🇺🇸

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath